WATERTOWN, Mass.--(BUSINESS WIRE)--FORMA Therapeutics announced today that Christine (Chris) P. Bellon, Ph.D., J.D., has been appointed to the position of Senior Vice President, General Counsel and Corporate Secretary. Chris joins the executive leadership team of FORMA with over 20 years of global experience in legal strategy, corporate partnerships and intellectual property, within the public and private Life Sciences sectors.

Chris comes to FORMA from Relay Therapeutics where she was Senior Vice President of Legal Affairs and contributed to the overall corporate, finance, business development and scientific strategy of the organization. Before joining Relay Therapeutics, Chris spent 5 years with Blueprint Medicines serving as their VP of Legal Affairs. She also previously served at Hydra Biosciences and Infinity Pharmaceuticals in varying legal and intellectual property leadership positions.

“Chris’ background spans a broad spectrum of legal areas. She has extensive experience working with both private and public emerging biotech companies,” said Steven Tregay, Ph.D., President and CEO, FORMA Therapeutics. “Chris brings to FORMA essential and in-depth experience which will be invaluable for meeting our strategic company objectives and, most importantly, ensuring that FORMA is successful in delivering on our promise of creating innovative medicines for patients who need them most.”

“I am thrilled to be joining FORMA at this stage of its growth and development,” said Chris Bellon. “FORMA’s drug discovery engine and network of collaborators have already demonstrated the capability to produce a broad and robust pipeline, and I am eager to contribute to this effort.”

Chris holds a juris doctor degree from Columbia Law School of New York and a Ph.D. in Organic Chemistry from Massachusetts Institute of Technology after graduating with a bachelor’s degree in Chemistry from Yale University.

About FORMA

FORMA Therapeutics’ scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The Company’s drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Leveraging a world class network of academic investigators, clinical experts and corporate partners, FORMA combines deep biological insight and chemistry expertise to rapidly create high quality, innovative drug candidates.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with an additional location in Branford, CT. www.formatherapeutics.com